ArticleEuropean journal of medical research2025
HEG1 promotes gastric cancer progression by stabilizing AKT1 and is functionally regulated by the deubiquitinase USP48.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- USP48 functions as a suppressor of colorectal cancer via SELENBP1 stabilization.Translational oncology · 2026Article
- The deubiquitinase USP35: from an oncogenic hub to a therapeutic target in human cancers.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHEG1 (Heart of Glass 1) is an endothelial cell-associated protein with emerging roles in oncogenesis, though its function in gastric cancer (GC) remains poorly understood. This study investigates the role of HEG1 in GC progression and uncovers the regulatory mechanism involving the deubiquitinase USP48.
methodsComprehensive bioinformatics analyses, in vitro and in vivo assays, were employed to evaluate the expression, function, and mechanistic regulation of HEG1 in GC. RNA-seq, protein interaction studies, immunoprecipitation assays, and pharmacogenomic data analysis were used to explore the HEG1-AKT1 axis and its modulation by USP48.
resultsHEG1 was significantly overexpressed in GC tissues and cell lines, and high HEG1 expression correlated with advanced tumor grade, TP53 wild-type status, and poor prognosis. Functional studies revealed that HEG1 promotes GC cell proliferation, clonogenicity, and tumor growth in vivo. Mechanistically, HEG1 stabilizes AKT1 by reducing its ubiquitination, leading to sustained activation of the AKT signaling pathway. Importantly, USP48 was identified as a novel deubiquitinase of HEG1. USP48 directly interacts with and stabilizes HEG1 by removing K48-linked polyubiquitin chains, thereby preventing proteasomal degradation.
conclusionHEG1 acts as a key oncogenic regulator in gastric cancer by modulating AKT1 stability and cell proliferative potential. Its stability is critically dependent on USP48-mediated deubiquitination. The USP48-HEG1-AKT1 axis represents a novel regulatory pathway in gastric cancer progression and a potential target for therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.